OneSource Specialty Pharma Q2 FY27 Earnings Call: EBITDA Up 53% on Operating Leverage, Line 2 Doubles Sterile Days

OneSource Specialty Pharma Ltd held its Q2 FY27 earnings call on October 27, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Operating Leverage Drives Outsize EBITDA Growth

• Revenue crossed Rs.5 billion in Q2 FY 2026-2027 — up 37% YoY and 15% QoQ; EBITDA grew 53% YoY and 32% QoQ, with margin expanding >400bps QoQ to 32%. Management attributed EBITDA outpacing revenue to operating leverage inherent in the business model.
• H1 FY 2026-2027 EBITDA grew 47% YoY — growth in both Q2 and H1 was driven by the additional DDC capacity that came online in Q2, contributing both commercial and MSA revenue.
• DDC cartridge line 2 operational since September (Q2 FY 2026-2027) — running commercial batches and immediately doubling sterile production days; geopolitics had delayed its start by almost 6 months.
• Both injectables and soft gel grew in Q2 FY 2026-2027 — with multiple launches across several markets; multiple regulatory and customer audits were also successfully completed in the quarter.
• Marginal FX impact on Q2 FY 2026-2027 results — CFO flagged a currency fluctuation impact quantified at about 300 (unit not specified on the call), called out separately in the public financials.

Line 2 Live, Line 3 in Qualification; Utilization Trajectory

• Line 2 doubles available sterile days on an annualized basis — management called this the key metric; it enables commercial ramp for Canada and other markets and MSA signings with pending existing and new customers, onboarding of whom had been stalled for the past year due to capacity constraints.
• Line 1 runs ~50,000–55,000 pens/day; with line 2, ~120,000–130,000 pens/day — yields vary by product and customer. Line 1 max batch is 200 liters (ramped from 30 liters at inception); line 2 is capable up to 750 liters with customers currently ramping to 500 liters.
• Line 3 completed its factory acceptance test in Germany — on site and ready for qualification (arrival delayed by extended Gulf transit times); management is making every effort for a Q4 FY 2026-2027 start, but commercialization might get pushed to the start of FY28; all three lines are expected fully operational for FY28.
• Utilization norm of 225–230 sterile days per year — management expects line 2 to reach this fairly rapidly given robust demand (constrained by media fills and quality reviews); line 3, slated for Q4 FY 2026-2027 or the first half of FY 2027-2028, is expected to follow the same pattern. No specific timeframe was given for scaling from 10-15% to 70-80% utilization.
• Steady-state line mix of 75% commercial / 25% MSA — CFO Anurag expects this for any line including line 2 (period unspecified); a representative Q2 FY27 MSA-to-CSA ratio was declined since MSAs commenced only from September 2026.
• Unit 2 (flagship site) capacity ramp of 2x to 3x targeted within FY 2026-2027 — CFO stated the company is on track.

Supply-Constrained Market; Canada, Brazil, India Runways

• Semaglutide remains supply-constrained rather than demand-constrained — across the US, Europe and newly off-patent markets (Canada, Brazil, India). India volumes rose from ~25,000 units/month in February (pre-patent expiry) to 200,000+ units/month as of September (Q2 FY 2026-2027); India chronic therapies typically take ~3 years to stabilize.
• Canada semaglutide market grew from 8 million to 12 million units — and stands at ~16-17 million units post-genericization as of Q2 FY 2026-2027; Dr. Reddy's had to exit the market and will be back as availability normalizes.
• Management cited market analysis indicating Canada and Brazil should be 4-6x their current sizes (period unspecified); OneSource holds all four approvals in Canada, multiple approvals in India, and has many Brazil customers waiting in the wings for approval.
• Brazil: only one generic (from a local Brazilian company) has launched so far — some customers have publicly announced approvals expected over the next quarter or two; CEO Neerag cited very high diabetes/obesity incidence and a strong local focus on body positivity and aesthetics as making Brazil a very interesting market.
• Hikma launched the first generic semaglutide in Saudi Arabia — an off-patent market; management highlighted it as the most significant launch of FY 2026-2027. Dr. Reddy's API has commenced, supporting a Canada relaunch and launches across multiple other markets where Dr. Reddy's already holds approvals.
• Beyond-FY28 DDC outlook — Europe starting to open in FY28-FY29; the big US market (with Western Europe) opening in FY30-FY31; emerging markets already showing significant growth — capacity expansion was sized accordingly.

Six New Wins; Biologics Funnel at Highest Ever

• 6 new order wins in Q2 FY 2026-2027 (slide 9 of the quarterly presentation), including 2 biologic products; the remaining 4 span biologics, DDC and the base business, covering both new launches and existing products.
• Two end-to-end development-to-commercialization biologics projects onboarded from a US biotech — plus an additional new program from one of the top global animal health companies (an existing customer), coming back-to-back after EU customer wins in the prior quarter.
• Biologics RFP funnel at its highest ever — with multiple projects in advanced stages, expected to drive growth beyond FY28; management cited the integrated "gene to device" offering and India's growing position as a trusted hub for global biologics/biosimilar development and manufacturing.
• All biologics revenue in the guidance period is pre-approval MSA (R&D) revenue — commercial revenue starts FY29 onwards and is of a "very different order of magnitude" than comparable small molecules.
• Base business adding pre-filled syringes and new lyophilization capacity — the planned site shutdown began at the back end of Q2 FY 2026-2027, with new capacity available from Q3 FY 2026-2027; management cited the FDA's shortage list — injectables contribute 70-75% of shortages, with lyophilization a big contributor — and flagged a big global supply-demand gap in lyophilization capacity.
• Soft gel capacity scaled almost 3x with additions begun in FY 2025-2026 — 80%+ capacity-utilization visibility already in place; with no further expansion possible at the current site, a greenfield soft gel site is planned to add capacity and enter containment and high-potency soft gels.
• Formycon: management declined comment on specific product or partnership details — including near first-to-file position — saying Formycon is a key customer and that with its customers OneSource has some of the largest products in the biosimilar space.

Cost Leverage Intact; Receivables Stretch Called Temporary

• Strong OpEx leverage underpins guidance — management highlighted that incremental cost is very limited versus incremental revenue, with EBITDA margins already improving quarter-on-quarter.
• Employee costs have risen steadily over the past 5-6 quarters (through Q2 FY 2026-2027) — due to a conscious hiring effort to build specialized, high-quality manufacturing capabilities.
• Trade receivables rose in H1 FY 2026-2027 — CFO Anurag attributed the increase to geopolitical disruptions (container availability, longer shipping lead times) stretching working capital cycles by 45-60 days, plus higher volumes; he stated there is no quality issue on the receivables and expects normalization within a quarter or two (by Q4 FY 2026-2027).
• Peers in the CFO community are experiencing ~2-3 percentage points of P&L impact from shipping/geopolitical disruptions; OneSource has no significant P&L impact since most of its raw material is pass-through, though fuel/freight costs and shipping-line availability are affected.
• Current effective tax rate to continue at least through Q3 FY 2027-2028 — CFO guided that brought-forward losses will be utilized against growing profits and will remain available at least for a significant part of FY 2027-2028.
• Consumables track manufacturing activity — fresh batches, engineering batches and volume ramp-ups drive quarter-to-quarter swings in this raw material line item (CFO Anurag).

FY28 Guidance Reaffirmed; Deleveraging and ROCE Path

• FY28 outlook reaffirmed at 400 million revenue and 160 million EBITDA — reiterated in response to Rupesh Tathya's (Long Equity Partners) $400 million reference, citing that all three lines will be available for FY 2027-2028. The analyst framed a Q4 FY 2026-2027 exit run-rate of ~$90 million revenue at 36-38% margin as within striking distance of that target.
• FY28 EBITDA of 160 million is a reported figure, not adjusted — CEO clarified all company EBITDA numbers are reported numbers (currency not specified in remarks).
• Management expects H2 FY 2026-2027 to be stronger than H1 FY 2026-2027 — supported by a significant commercial volume ramp-up on the new DDC capacity; supply ramp-up from other Canadian customers is on track for Q3 FY 2026-2027.
• DDC's share of FY28 sales not quantified — when asked whether it could be ~50% or higher against the 400 million FY28 guidance, management stated only that DDC will remain a very strong contributor to FY28 numbers, including the second half of FY28. FY28 blended realizations are seen as broadly stable, with pricing volume-based rather than market-based.
• Debt levels of ~1.5x EBITDA to continue — CFO Anurag said the company will remain at these levels (period unspecified) while in a significant investment cycle, and will continuously move toward generating free cash going forward.
• ROCE returns anticipated to reach the high 20s% by end of FY28 — CEO Neeraj endorsed the FY28 goal, stating the company is "clearly moving forward towards that goal."
• No beyond-FY28 growth guidance issued yet — management will provide an outlook during FY28; 12 launches are planned in FY 2026-2027 spanning soft gelatin, injectables and geographies (US, Europe, emerging markets), with newly added injectables capacity to be filled over the next 2-3 years.